StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$16.70+0.80 (+5.03%)

Close on Nov 17, 2026Market cap $1.65BP/E –Yield –

Ultragenyx Pharmaceutical enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Ultragenyx Pharmaceutical's enterprise value was $1.35B on Nov 11, 2026, against $2.93B a year earlier. Over the last 5 years it ranged from $1.19B to $4.98B, with a median of $2.74B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.35B-24.4%
2025Dec 31, 2025$1.79B-45.0%
2024Dec 31, 2024$3.26B+8.4%
2023Dec 29, 2023$3.01B+27.6%
2022Dec 30, 2022$2.36B-52.6%
2021Dec 31, 2021$4.98B-35.0%
2020Dec 31, 2020$7.65B+294.6%
2019Dec 31, 2019$1.94B+14.5%
2018Dec 31, 2018$1.69B+5.9%
2017Dec 29, 2017$1.60B-33.9%
2016Dec 30, 2016$2.42B-38.1%
2015Dec 31, 2015$3.91B+226.6%
2014Dec 31, 2014$1.20B–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?